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When normal plasma comes in contact with negatively charged surfaces  suc, 
glass, kaolin, and connective tissue, a group of  plasma proteolytic enzymes is activated. 
The proteins that have been identified as being involved in this contact reaction are: 
Hageman factor (factor XII), Fletcher factor (prekallikrein),  and Fitzgerald factor 
(high molecular weight kininogen, HMWK).a The interaction of  these plasma proteins 
on a negatively charged surface results  in the activation of factor XI, prekallikrein, 
and plasminogen (1-11).  Congenital deficiencies  in any of these proteins result in 
abnormalities of the intrinsic clotting and fibrinolytic pathways and in the formation 
of kinins (5-11). 
Until the Fitzgerald trait (HMWK deficiency)  (8) was discovered,  the only known 
role of HMWK was as a substrate for plasma kallikrein. Now it is also recognized as 
a necessary component for the activation by contact of the above-mentioned proteo- 
lytic pathways. Data from our laboratory (12) and from others (13) have shown that 
purified bovine high molecular weight kininogen (bHMWK) partially corrects  the 
prolonged activated plasma thromboplastin time (aPTT)  and the kaolin-activated 
euglobulin-lysis time of Fitzgerald-trait plasma. Several investigators have found that, 
while hydrolysis of human HMWK (hHMWK) by human plasma kallikrein results 
in  kinin  release,  the ability of kinin-free HMWK to correct  the abnormalities of 
Fitzgerald-trait plasma is not affected (11, 14-16). Hydrolysis of bHMWK by bovine 
plasma kallikrein results  in the release of a  large peptide (fragment 1-2) as well as 
bradykinin. The bradykinin-fragment 1-2-free bHMWK had almost no correcting 
activity when  tested on  Fitzgerald-trait plasma  (12, 13). These  differences  in  the 
correcting activity of both human and bovine kininogens after hydrolysis may be due 
to a lack of fragment 1-2 cleavage from the hHMWK by plasma kallikrein. 
To determine whether fragment 1-2 is necessary  for bHMWK correcting activity, 
* Partially supported by Michigan Heart Association and a  Ford  Foundation grant to  Henry  Ford 
Hospital; these data were presented at Vhh International Congress on Thrombosis and Hemostasis held 
in Philadelphia, 1977. Thromb.  Haemostasis.  $8:14. 
1 Abbreviations used in this paper:  aPTT,  activated plasma thromboplastin time; bHMWK, bovine high 
molecular  weight  kininogen;  Brk,  bradykinin;  HCH,  heavy  chain;  HMWK,  high  molecular  weight 
kininogen;  hHMWK,  human  HMWK;  LCH,  light chain;  LMWK,  low  molecular weight  kininogen; 
SBTI, soy bean trypsin inhibitor. 
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kinin-free  bHMWK  with  intact  fragment  1-2  was  tested  for its  correcting activity 
upon the aPTT  of Fitzgerald-trait  plasma.  Also to examine whether bovine plasma 
kallikrein  decreases  the  correcting  activity  of hHMWK,  these  two  proteins  were 
incubated and the correcting activity of the mixture was determined. 
To clarify the relationship  between the structure and the function of HMWK,  the 
correcting activity of various isolated fragments of bHMWK  was studied. Because we 
previously reported that fragment  2  (histidin-rich  fragment)  has an inhibitory effect 
upon the clotting time of normal human plasma, the inhibitory activity of fragment 
1-2 was also studied. 
Materials  and Methods 
Reagents and Chemicals.  Sodium barbital,  NaCI, acid-washed kaolin  (Fisher Scientific Co., 
Pittsburgh,  Pa.), CaCI2 anhydrous (J. T. Baker Chemical Co., Phillipsburg,  N.J.) were com- 
mercially obtained. HMWK-deficient plasma was obtained directly from Mr. Fitzgerald. Nine 
parts of blood were mixed with one part  of 3.8% sodium citrate.  Plasma was separated  by 
centrifugation, distributed in 3-mi aliquots in polystyrene tubes, and kept frozen at -70°C. 
Purified Bovine Proteins.  bHMWK was purified and characterized as described elsewhere (17, 
18). Prolonged incubation with bovine plasma kallikrein  releases  bradykinin,  fragment  1-2, 
and,  later on, fragments  1 and  2. These fragments have been characterized  (18-20).  Heavy 
chain and light chain were further obtained by reduction and alkylation of the bradykinin- 
fragment 1-2-free-bHMWK (21). Lys-bradykinin-free-bHMWK was obtained by treatment of 
bHMWK  with  human  urinary  kallikrein  as  previously published  (22).  Fragment  1-2-light 
chain  was  obtained  by reduction  and  alkylation  of the  lys-bradykinin-free-bHMWK  and 
characterized as described (22). Purified bHMWK was obtained by the method of Guimaraes 
et  al.  (23).  1 mg of lyophilized  kininogen  has  8.5  times  more  correcting  activity  on  the 
Fitzgerald-trait  plasma  aPTT  than  1 ml  of a  pool of normal  human  plasma.  Assessed  by 
polyacrylamide gel electrophoresis (20 #g), it revealed three major bands and two faint bands. 
When eluted  from one unstained  gel  and  tested on Fitzgerald-trait  plasma aPTT,  all  three 
major  bands  revealed  clotting  activity.  This  hHMWK contained  no  detectable  Hageman 
factor, prekallikrein, factor XI, plasminogen, or a2-macroglobulin. 
Kaolin  aPT'F  The  correcting  activity  of HMWK  and  its  fragments  on  the  aPTT  of 
Fitzgerald plasma was tested by adding the following in a polystyrene tube: 0.1 ml of Fitzgerald 
plasma, 0.1 ml of the test substance in Owren's buffer, and 0.1 ml of cephalin-kaolin suspension 
(10 mg of acid-washed kaolin suspended in 1.0 ml of cephalin). This mixtue was preincubated 
at 37°C for 8 min, and then 0.1 ml of  0.2 M CaCI2 was added and the clotting time determined. 
Inhibition  of the  aPTT of Normal  Plasma  by  Fragment  1-2  and  Fragment  2.  Cephalin-kaolin 
suspension (0.1 ml) was incubated for 1 min with an Owren's buffer solution of the fragment 
to be tested (0.1 ml). Normal plasma (0.1 ml) was added and the mixture incubated for 3 min. 
After the addition of 0.02 M CaCI2 (0.I ml), the clotting time was determined. 
Comparison of the Correcting Activity  of bHMWK and its Fragments on the aPTT of Fitzgerald- Trait 
Plasma on a Molar and on a  Weight Basis.  Intact bHMWK (mol wt 76,000);  lys-bradykinin-free 
bHMWK  (mol  wt  75,000);  bradykinin-fragment  1-2-free  bHMWK  (tool  wt  66,000);  and 
fragment l-2-1ight chain (mol wt 48,500) were dissolved in Owren's buffer at concentrations of 
1.32, 0.26, and 0.13 nmol/ml. The correcting activity of 0.1 ml of each solution was tested upon 
Fitzgerald-trait  plasma aPTT.  Simultaneously, the correcting activity of serial  dilutions of a 
pool of normal human plasma and its fragments was determined. This curve was then used to 
calculate the correcting activity of bHMWK and its fragments in U/nmol.  1 U of correction is 
defined as the correcting activity of 200 #1 of normal human plasma. 
For comparison of the correcting activity of bHMWK and its fragments on a weight basis, 
100 #g of each of the prelyophilized test materials were dissolved in 1.0 ml of Owren's buffer, 
and 0.1 ml was used to determine their correcting activity upon Fitzgerald plasma aPTT. 
Effects of Bovine Plasma Kallikrein  on the Correcting Activity of Human and Bovine HMWK.  Purified 
bovine plasma kallikrein  (0.28 #g) and hHMWK (95 #g) were dissolved in  1.0 ml of Owren's 
buffer (pH 7.5) and incubatedat  37°C for 30 and 60 min. At these times, two aliquots of 20 SCICLI ET AL. 
TABLE I 
Comparison on a Molar Basis of the Correcting Activity of Bovine HMWK and its 
Fragments on Fitzgerald-  Trait Plasma aPTT 
849 
Protein  Normal plasma 
%  U/nmol 
HMWK  2.5  0.10 
Lys-hradykinin-free HMWK  5.6  0.22 
Bradykinin and fragment 1-2-free  HMWK  0.8  0.03 
Fragment 1-2-light chain  2.5  0.10 
Light chain  0.1  0.004 
Heavy chain  No activity  0 
All proteins were tested at 0.26 nmol/ml. 
TABLE II 
Comparison on a  Weight Basis of the Correcting Activity of Bovine HMWK 
and Fragments on Fitzgerald-  Trait Plasma aPTT 
Protein 
U/mg 
HMWK  1.2 
Lys-bradykinin-free HMWK  1.7 
Bradykinin and fragment 1-2-free  HMWK  0.3 
Fragment 1-2-light  chain  2.6 
Light chain  0.1 
Heavy chain  0 
Fragment  1-2  Inhibits 
Fragment 2  Inhibits 
All proteins were tested at  100 ~g/ml. 
gl each of the incubation mixture were taken. One of the atiquots was diluted by mixing it with 
80 #1 of Owren's buffer. The correction upon the aPTI" of Fitzgerald-trait plasma was tested 
immediately. The second aliquot was mixed with 1.980 #1 of a solution of 0.1 M SBTI in 0.1 M 
Tris-HCl  buffer (pH  7.4). This  mixture was immersed  in a  boiling water bath  for  10 min, 
centrifuged, and the kinins measured.  The same procedure was used with bHMWK (50 ~tg) 
except that 100 #1 of undiluted incubation mixture was used for testing its Fitzgerald correcting 
activity. When human and bovine HMWK were incubated with trypsin (24), they released 8.7 
and 8.0/~g of kinins/mg of protein, respectively. Kinins were tested by a radioimmunoassay 
(25). 
Results 
The correcting activity of the different purified bovine proteins, when expressed in 
U/nmol, was not affected by the three different concentrations tested.  The exception 
to this result was lys-bradykinin-free bHMWK,  in which the specific activity doubled 
with a  10-fold dilution. 
Table I shows the correcting activity of intact bHMWK  and its different fragments 
expressed  in  U/nmol  of proteins,  when  tested  at  a  concentration  of 0.26  nmol/ml. 
Table II shows the correcting activity expressed as U/mg  of proteins. Table III shows 
the effect of fragment  1-2 and  fragment  2  on the aPTT  of normal  human  plasma. 
Table IV shows the effects of bovine plasma  kallikrein  on the Fitzgerald  correcting 
activity of human and bovine HMWK. 850  BOVINE  HIGH  MOLECULAR  WEIGHT  KININOGEN 
TAaLE III 




Fragment 2 (tool wt 4,600)  21.7  320 
Fragment 1-2 (mol wt  12,600)  19.8  139 
Normal plasma aPTT was 45 s. 
TABLE  IV 
Effect of Bovine Plasma Kallikrein on the Correcting Activity of Human and Bovine HMWK on 
Fitzgerald-Trait Plasma aPTT 
Human HMWK  Bovine HMWK  Time of incuba-  Human HMWK  Bovine HMWK  and bovine kalli-  and bovine kalli-  tion  --  krein  krein 
rain 
0  73  71  91  103 
30  72  74 (240)  --  149 (265) 
60  76  72 (300)  98  200 (375) 
Number indicates aPTT  in seconds. Numbers in  parentheses indicate  ng of kinins released by bovine 
plasma kallikrein. 
Discussion 
High molecular weight kininogen seems to be essential for the contact activation of 
the intrinsic coagulation pathway (26). We have tried to determine which region of 
the  HMWK molecule is  responsible  for  the  correction  of Fitzgerald  trait  plasma 
aPTT.  For this we  have  used  bHMWK, which  is  known to  partially correct  the 
abnormalities in the aPTT of HMWK-deficient human plasma (12,  13). 
Intact bHMWK has a mol wt of ~76,000 daltons. Of these, 48,500 are contributed 
by the heavy chain;  1,000 by bradykinin; 12,600 by fragment 1-2; and 16,000 by the 
light chain (I 7). Because the fragments of bHMWK are present in the intact molecule 
in  equimolar  concentration,  their  activity must  be  expressed  on  a  molar  base  to 
compare their relative correcting activity. Fig.  1 shows a schematic representation of 
the structure of bHMWK and its fragments and the relative correcting activity of 
equimolar concentration of each protein. Intact bHMWK was arbitrarily assigned a 
correcting activity of 100%. 
Our  findings  indicate  that  a  peptide  formed  by  fragment  1-2-light  chain  is 
responsible  for the  Fitzgerald correcting  activity of bHMWK.  Fragment  1-2-light 
chain is as active as intact bHMWK on a molar basis, and virtually more than twice 
as active on a weight basis. 
As expected, we found that the heavy chain of bHMWK has little or no correcting 
activity, because it is chemically and immunologically common to both low and high 
molecular weight kininogen; and low molecular weight kininogen lacks correcting 
activity (12).  Although the  heavy chain  is  not  essential  for the  expression  of the 
coagulant activity of bHMWK, it may play a permissive role, because lys-bradykinin- 
free  bHMWK  (which  includes both  the  heavy chain  and  the  fragment  1-2-light 
chain) is more active on a  molar basis than fragment 1-2-light chain (Table I). It is 
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Fio.  1.  Relative correcting activity of equimolar concentration of bovine HMW kininogen and its 
fragments.  The correcting activity of intact bovine HMWK was arbitrarily assigned  100%. 
better steric relationship with Hageman factor and/or prekallikrein and  factor XI, 
than  fragment  l-2-1ight  chain  or  bHMWK.  This  would  favor  a  more  effective 
interaction on the surface. 
We  have  observed  an  increase  in  the  specific  activity  of  lys-bradykinin-free 
bHMWK with higher dilutions. This increase may be due to the presence of trace 
amounts of a contaminant with inhibiting capacity, such as fragment 1-2 or fragment 
2, in the preparation. 
Fragment  1-2-light chain was obtained by reduction of the disulfide bonds of the 
lys-bradykinin-free bHMWK,  followed by alkylation of the thiol groups. It retains 
full activity in the coagulation assay, which suggests that intact disulfide bonds are 
not necessary for the Fitzgerald correcting activity of bHMWK. 
The light chain without fragment 1-2 lacks functional activity, indicating that the 
fragment  1-2 peptide, or part of it (fragment 2), plays a crucial role in the initiation 
of the intrinsic coagulation system. It was also observed that fragment  1-2 and, to a 
greater degree, fragment 2 have a marked capacity to inhibit the surface activation of 
the coagulation pathways of normal human plasma, but only if the fragment  1-2 or 
fragment 2 was added before or during the incubation of normal plasma with kaolin. 
This  observation  suggests  that  when  fragment  1-2  and  fragment  2  bind  to  the 
negatively charged surface, they competitively inhibit the binding and activation of 
the proteins involved in the intrinsic coagulation pathway. 
Considering these results, we propose that the fragment  1-2 portion serves to bind 
HMWK to the negatively charged surfaces, and  that  the light chain, or part  of it, 
interacts  with  Hageman  factor and/or  prekallikrein  and  factor XI.  Furthermore, 
because Wiggins et al. (27) have clearly shown that the activation of factor XI occurs 
only on the surface, we propose that  the light chain without fragment  1-2  (binding 
site) lacks activity because it will remain in the fluid phase. It may be speculated that 
HMWK complexed with prekallikrein and factor XI in the fluid phase (28, 29) can 852  BOVINE HIGH MOLECULAR WEIGHT KININOGEN 
carry these proteins to negatively charged surfaces. On  the surface, the interaction 
between Hageman factor, HMWK, prekallikrein, and factor XI will activate all the 
Hageman-dependent pathways, such as intrinsic coagulation, fibrinolytic, kallikrein- 
kinin, and complement systems. 
There  are  some  differences  as  well  as  similarities  between  bovine  and  human 
HMWK. Bovine plasma kallikrein destroys the correcting activity of bHMWK, while 
human  plasma  kallikrein does not  affect the activity of hHMWK.  This difference 
could be due to an enzymatic contamination in the bovine plasma kallikrein prepa- 
ration. When hHMWK was incubated with bovine kallikrein, kinins were released 
although  there  was  no  loss  of functional  activity.  It  is  therefore unlikely  that  a 
contaminating enzyme is present in the bovine plasma kallikrein preparation, unless 
the hypothetical contaminating enzyme has species specificity. It is more probable 
that the reason for the different behavior of bHMWK and hHMWK after hydrolysis 
with homologous plasma kallikrein can be explained by structural variations between 
both  substrates.  The  fact  that  the  bovine plasma  has  only  7-12%  (12,  30)  of the 
correcting  activity  of human  plasma  also  points  to  partial  structural  differences 
between bHMWK and hHMWK. Furthermore, we have found that if fragment  1-2 
remains attached to the light chain of bHMWK, the Fitzgerald correcting activity is 
also retained. Because hHMWK retains full correcting activity after hydrolysis with 
bovine  or  human  plasma  kallikrein,  we  conclude  that  neither  enzyme is  able  to 
separate the basic peptide, equivalent to fragment 1-2, from hHMWK. 
Recent evidence indicates that human kininogen shares the same basic structures 
with its bovine counterpart. Nagasawa et al.  (31)  have reported that hHMWK is a 
linear glycoprotein in which the bradykinin moiety is included in the inner portions. 
Human kallikrein acts upon hHMWK, releasing bradykinin and leaving a kinin-free 
HMWK  which  has  a  heavy  and  a  light  chain  linked  by  a  disulfide  loop  as  in 
bHMWK.  It has been shown that antibodies against  human  low molecular weight 
kininogen cross-react with human high molecular weight kininogen (28-32). Similarly, 
antibodies against bovine low molecular weight kininogen (bLMWK) cross-react with 
bHMWK (21). 
It  is known  that  both bLMWK and  human  LMWK  (hLMWK)  lack correcting 
activity upon  Fitzgerald-trait plasma  aPTT (10-13).  Antibodies against  hHMWK, 
after adsorption with Fitzgerald-trait plasma  (which has LMWK), no longer cross- 
react with hLMWK. When tested against hHMWK, a precipitation line is observed 
(14, 33). This suggests the presence of  antigenic determinants in the HMWK molecule, 
which  are  not  present  in  the  LMWK.  It  is  logical  to  assume  that  the  antigenic 
determinants  of the  HMWK  not  present  in  the  LMWK  are  responsible  for  the 
hHMWK coagulating activity. 
Komiya et  al.  (17)  and  Kato  et  al.  (21)  have  reported  that  the  bLMWK  and 
bHMWK differ in their light chains, and we have shown that the correcting activity 
of the bHMWK resides precisely in the fragment  1-2 light chain. To complete the 
resemblance between the bovine and human kininogen, it has been reported (33) that 
the light chain enables the hHMWK to correct the aPTT of Fitzgerald-trait plasma. 
However, a positively charged peptide similar to the bovine fragment  1-2 has yet to 
be identified in the light chain of the hHMWK. 
It is interesting that plasma of patients such as Flaujeac and Williams (10, 11) lacks 
both LMWK and HMWK, functionally and  immunologically, although Fitzgerald SCICLI  ET AL.  853 
plasma lacks only HMWK. It seems unlikely that the first group is deficient in more 
than one gene. It is more likely that both kininogens are synthesized by the expression 
of different but closely related genes. We speculate that the heavy chain, which is 
probably common to both forms of kininogen, might be synthesized through a  gene 
(A) which might be linked to a regulatory gene in a lae operon. The addition of the 
fragment 1-2 light chain may be regulated by a gene (B), whereas the addition of the 
light chain of LMWK may be regulated by a gene (C). Genes (A), (B), and (C) might 
be structural genes. Within this context, a lack of expression of gene (A) will produce 
a  deficiency in both LMWK and HMWK. A  deficiency in the structural gene (B) 
might  still  allow  the  synthesis of LMWK  (Fitzgerald-trait).  Therefore,  it  can  be 
predicted that a deficiency of LMWK, but not of HMWK, will eventually be found. 
Summary 
Bovine high molecular weight kininogen (bHMWK) partially corrects the activated 
plasma thromboplastin time (aPTT) of Fitzgerald trait plasma which is congenitally 
deficient in HMWK. The relationship between the structure and activity of HMWK 
was clarified by studying the effects of different fragments of bHMWK on the aPTT 
of Fitzgerald-trait plasma. The peptides studied were lys-bradykinin-free HMWK, 
bradykinin-fragment  1-2-free  HMWK, heavy chain, fragment  1-2-light chain, and 
light  chain.  All  fragments  were  tested  in  equimolar  concentrations.  Bradykinin- 
fragment 1-2-free  HMWK, heavy chain, and light chain have little or no correcting 
activity upon Fitzgerald-trait plasma aPTr. Fragment 1-2 light chain has the same 
correcting  activity as  intact  bHMWK,  while  that  of lys-bradykinin-free HMWK 
appears to be higher. Both fragment 1-2 and fragment 2 inhibit the clotting time of 
normal human plasma. When compared on a molar basis, fragment 2 is a more active 
inhibitor  than  fragment  1-2. When  the  effects of bovine  plasma  kallikrein  upon 
bHMWK and hHMWK were studied, it was found that it released kinins from both 
kininogens.  However,  while  the  correcting  activity  of bHMWK  was  completely 
destroyed after 60 min of incubation, that of hHMWK was fully retained. These data 
suggest that:  (a)  the active part of bHMWK is comprised of the fragment 1-2 light 
chain portion; (b) fragment 1-2 or fragment 2 is the binding site to negatively charged 
surfaces, while the light chain interacts with other components of the surface-mediated 
reactions;  and  (c)  bovine plasma kallikrein releases  kinins, but  probably  does not 
cause the release of fragment 1-2 from human HMWK. 
Received  for publication 18 September 1978. 
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